Health

The Biosimilar Bylaw Bind: Why Your Cheap Biosimilar Now Requires Three Departmental Sign-Offs Before Insurance Approval

WASHINGTON, D.C. — The FDA’s new biosimilar pricing transparency initiative, announced last Tuesday with the solemn gravitas of a coroner reading a death certificate, has inadvertently created the administrative equivalent of a hamster trapped in a centrifuge. According to preliminary industry estimates, what was once a straightforward 48-hour insurance pre-authorization process for a generic biosimilar antibody has now evolved into a multi-departmental approval marathon requiring coordination between the FDA’s Division of Biologics Review, the CMS Drug Pricing Office, the Department of Consumer Affairs’ Pharmacy Benefit Unit, and what is reportedly being referred to internally as “The Office of Bureaucratic Friction.”

Virtual Reality Therapists Accused of 'Manufacturing Trauma' After Patients Claim Their Simulated PTSD Is Too Authentic for Insurance Coverage

When you first sit in the waiting room of Metaverse Mental Health Centers’ virtual clinic, the receptionist—a 3D avatar named ‘TherapyBot 3000’—gently explains that all appointments are scheduled through the portal.

“This is to ensure we maintain optimal ‘presence metrics’ for your therapeutic journey,” they say with a smile that flickers between wireframe and photorealistic depending on your network connection.

For the $89 per session fee, patients can choose from a rotating roster of simulated scenarios: a sinking ship where you’re responsible for a lost colleague’s family dog, a breakup where the ex keeps texting during therapy sessions, or the ever-popular “accidentally stepping in dog poop at a wedding” vignette, which is currently in the “high demand” category.